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Spinocerebellar ataxia type-3 (SCA3) is among the most common dominantly inherited ataxias, and is one of nine
devastating human neurodegenerative diseases caused by the expansion of a CAG repeat encoding glutamine within
the gene. The polyglutamine domain confers toxicity on the protein Ataxin-3 leading to neuronal dysfunction and loss.
Although modifiers of polyglutamine toxicity have been identified, little is known concerning how the modifiers
function mechanistically to affect toxicity. To reveal insight into spinocerebellar ataxia type-3, we performed a genetic
screen in Drosophila with pathogenic Ataxin-3-induced neurodegeneration and identified 25 modifiers defining 18
genes. Despite a variety of predicted molecular activities, biological analysis indicated that the modifiers affected
protein misfolding. Detailed mechanistic studies revealed that some modifiers affected protein accumulation in a
manner dependent on the proteasome, whereas others affected autophagy. Select modifiers of Ataxin-3 also affected
tau, revealing common pathways between degeneration due to distinct human neurotoxic proteins. These findings
provide new insight into molecular pathways of polyQ toxicity, defining novel targets for promoting neuronal survival
in human neurodegenerative disease.
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Introduction
Spinocerebellar ataxia type 3 (SCA3) is the most common
dominantly inherited ataxia worldwide and is caused by a
CAG repeat expansion encoding glutamine within the ATXN3
gene [1,2]. The expanded polyglutamine (polyQ) is thought to
confer toxicity on the protein Ataxin-3, leading to neural
dysfunction and loss [3]. At least nine human diseases,
including additional spinocerebellar ataxias and Hunting-
ton’s disease, share this mechanism. Studies on such
pathogenic proteins reveal that the long polyQ domain alters
protein conformation, causing an enriched beta sheet
structure [4]. Mutant polyQ protein also dynamically asso-
ciates with chaperones and colocalizes with proteasome
subunits, indicating that the protein is misfolded or
abnormally folded [5,6]. Such accumulation of misfolded
protein is a common pathology of human degenerative
disorders, including Alzheimer, Parkinson, and prion diseases
[7–9], indicating that these diseases may share molecular and
cellular mechanisms.
Models for human neurodegenerative diseases in simple
systems have provided valuable tools to dissect molecular
mechanisms of disease pathology [10–13]. Directed expres-
sion of pathogenic human Ataxin-3 in Drosophila recapitulates
key features of disease, with late-onset neuronal dysfunction
and degeneration accompanied by ubiquitinated inclusions
[14,15]. Neurotoxicity is more severe with increasing length of
the polyQ repeat, similar to the human disease where longer
repeats are associated with more severe and earlier onset
disease [16,17]. In the ﬂy, increased levels of expression of the
disease protein leads to more severe degeneration and earlier
onset protein accumulation, suggesting that abnormal accu-
mulation of the mutant protein is central to disease and
degeneration.
A number of modiﬁers of select polyQ disease proteins
have been identiﬁed using animal models, including chaper-
ones, transcriptional coregulators, and microRNAs [18–22].
Although these approaches have revealed genes that modu-
late polyQ toxicity, little is known regarding how the
modiﬁers act biologically to modulate polyQ degeneration.
Among polyQ proteins, Ataxin-3 is unique because it has
been implicated in ubiquitin pathways, and its normal activity
may impinge on protein degradation pathways [23–26].
Truncation of Ataxin-3 to remove the ubiquitin protease
domain, or mutation of the ubiquitin protease activity,
dramatically enhances toxicity [15], indicating that the
normal activity of Ataxin-3 may be critical in Ataxin-3-
induced degeneration. To reveal insight into pathways that
modulate Ataxin-3 neurodegeneration, we performed a
genetic modiﬁer screen in Drosophila. These studies revealed
a range of modiﬁers that, despite some broadly diverse
predicted molecular functions, converge on protein misfold-
ing with a subset mitigating toxicity through proteasome and/
or autophagy pathways. These ﬁndings underscore the critical
role of protein quality control in SCA3 pathogenesis and
provide potential new targets toward therapeutics.
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A Genetic Screen Defines Modifiers of Pathogenic Ataxin-
3 Toxicity
To deﬁne modiﬁers that may reveal new insight into
mechanisms of human SCA3 disease, we performed an
overexpression screen for modiﬁers of Ataxin-3-induced
neurodegeneration in Drosophila. SCA3trQ78 causes late
onset progressive degeneration characterized by loss of
pigmentation and collapse of the eye (Figure 1A and 1B)
[14]. We initially screened a subset of 2,300 available EP-
element insertion lines, each carrying a transposon engi-
neered to direct expression of the downstream gene in the
presence of the yeast GAL4 protein [27]. Because reprodu-
cibility was variable with this collection, we then performed a
screen de novo, selecting for new EP-insertions that modiﬁed
SCA3trQ78 toxicity. This approach identiﬁed 17 suppressors
and one enhancer (Figures 1C–1J and S1), which affected
both external and internal retinal degeneration.
Plasmid rescue was performed to identify the genes
affected. BLAST searches with genomic sequence from the
integration sites revealed that the lines bore insertions in the
59 regulatory region of select genes, and all were in an
orientation to direct GAL4-dependent gene expression (Text
S1; Table S1). Northern and reverse transcription PCR
analysis conﬁrmed upregulation of the targeted genes; using
a variety of tests we conﬁrmed that the modiﬁers did not
appear to affect transcription of the Ataxin-3 transgene or
general GAL4-UAS transgene expression (Figure S2). Both
molecular and genetic analyses conﬁrmed that the insertions
were single insertions (see Materials and Methods). Reversion
analysis proved that the EP-elements were causal in mod-
iﬁcation. Taken together, these data indicated that the EP
modiﬁers resulted in increased expression of the targeted
downstream genes, which modulated SCA3trQ78 toxicity and
neurodegeneration.
Molecular Analysis Implicates Diverse Biological Pathways
Analysis of the targeted genes revealed that the majority
fell into two major classes of chaperones and ubiquitin-
pathway components (Table 1; Figures S1 and S3). The
remaining modiﬁers were placed in a third category of
miscellaneous functions. Class 1 (Figure 1C–1E) included an
Hsp70 family member, Hsp68
E407; two Hsp40 genes, DnaJ-
1
B345.2 and mrj
E1050; a small heat shock protein aB crystalline
CG14207
EP1348; and the cochaperone Tpr2
EB7-1A. The class 2
ubiquitin-pathway components included: polyubiquitin
CR11700
EP1384; a ubiquitin-speciﬁc protease Ubp64E
E213-1A;
two ubiquitin ligases, CG8209
B3-Sa and Faf
E659; and an F-box
protein CG11033
EP3093, the only enhancer of the group. Class
3 (Figure 1F and 1G) included genes with a variety of
predicted molecular functions: the nuclear export protein
Embargoed, emb
E2-1A and emb
E128-1A; three transcriptional
regulators Sin3A
B9-E, NFAT (NFAT
EP1335 and NFAT
EP1508),
and debra (dbr
EP456 and dbr
EP9); three translational regulators,
including four alleles of the lin-41 homologue dappled
(dpld
JM120, dpld
JM265, dpld
EP546, and dpld
EP2594), a polyA bind-
ing protein orb2
B8-S, and insulin growth factor II mRNA
binding protein Imp
EP1433; and ﬁnally a fatty acid oxidation
enzyme palmitoyl co-A oxidase CG5009
B227.2. This indicated
that, although chaperone and ubiquitin-pathway components
are major modiﬁer categories, a variety of functional path-
ways are implicated in Ataxin-3 pathogenesis.
The screen selected for modiﬁers that, upon upregulation,
affected toxicity. To determine whether the activity of these
genes may normally play a role in SCA3 toxicity, we examined
whether reduction in the level of the modiﬁer genes had an
effect. To do this, we reduced gene expression by 50% using
loss-of-function alleles where available or deﬁciency lines.
Among these, reduction with a deﬁciency of DnaJ-1 and
Ubp64E (within the same deﬁciency; reduction of DnaJ-1 has
previously been shown to enhance with a dominant-negative
construct [16]), Trp2, emb (with an allele), and dbr dramatically
enhanced degeneration (Figure1K–1O; Table S2). Although
the deﬁciencies reduce the level of a number of genes, these
data suggest that the endogenous activity of these genes may
normally help to protect against degeneration.
To address whether morphological rescue correlated with
functional rescue, we determined the ability of select
suppressors to restore function in a phototaxis assay. When
ﬂies bearing the SCA3trQ78 protein were given a choice
between a light and dark chamber, they distributed randomly,
indicating that they are functionally blind (Figure 1P).
However, when mrj
E1050, which dramatically rescued degen-
eration, was co-expressed, normal vision was restored. A
milder suppressor that anatomically restored less retinal
tissue, CG14207
EP1348, restored vision partially. Thus, ana-
tomical rescue correlated with functional rescue. These and
other studies indicated that the modiﬁers not only modulated
toxicity of the external eye, but also that of the neuronal cells.
To conﬁrm this in another situation, we tested select
modiﬁers for the ability to mitigate polyQ toxicity when
directed exclusively to the nervous system with elav-GAL4
(Figure S4). These studies conﬁrmed that the modiﬁers
mitigated neuronal toxicity of the Ataxin-3 protein.
We performed select additional experiments with dpld, for
which we obtained many independent EP overexpression
alleles. These detailed studies conﬁrmed activity of the EP
alleles of dpld with independent UAS-dpld transgenic lines.
Further, suppression by dpld was not limited to development
but also extended to the adult timeframe (Figures S2, S5, and
S6).
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Author Summary
Spinocerebellar ataxia type-3 is the most common dominantly
inherited movement disorder and is caused by a CAG repeat
expansion within the gene ATXN3, encoding the Ataxin-3 protein.
This leads to a protein with an expanded polyglutamine domain,
which confers a dominant toxicity on the protein, leading to late
onset, progressive neural degeneration in the brain. Although some
modifiers of Ataxin-3 toxicity have been defined, little was known
about their molecular mechanisms of action. The fruit fly Drosophila
recapitulates fundamental aspects of the human disease. Here, we
performed a genome-wide screen for new modifiers of Ataxin-3
toxicity using the fly and defined 25 modifiers in 18 genes. The
majority of the genes belong to chaperone and ubiquitin
proteasome pathways, which modulate protein folding and
degradation, but the remaining modifiers have a broad range of
predicted molecular functions. Assays in vivo revealed that the
biological activity of all modifiers converge on aiding in situations of
protein misfolding, despite distinct predicted molecular functions.
Select modifiers of Ataxin-3 toxicity also modulated tau toxicity
associated with Alzheimer disease. These findings underscore the
importance of protein homeostasis pathways to disease and provide
the foundation for new therapeutic insight.PLoS Genetics | www.plosgenetics.org October 2007 | Volume 3 | Issue 10 | e177 1952
Modifiers of Ataxin-3 NeurodegenerationBecause the genes were isolated as modiﬁers of a truncated
Ataxin-3 protein, we tested whether they could mitigate
toxicity of full-length Ataxin-3, which is largely a neuronal
toxicity [15]. Modiﬁers that phenotypically strongly sup-
pressed toxicity of truncated Ataxin-3 also strongly sup-
pressed full-length Ataxin-3 toxicity; however, a number of
modiﬁers that were weak or moderate suppressors of the
truncated protein were, in contrast, strong suppressors of
full-length Ataxin-3: CG14207
EP1348 (aBc r y s t a l l i n e ) ,
CR11700
EP1384 (polyubiquitin), CG8209
B3-Sa (putative ubiqui-
tin ligase), and Sin3A
B9-E (Figure S7 and unpublished data).
Consistent with strong anatomical rescue, CG14207
EP1348 also
robustly suppressed functional vision defects of full-length
Ataxin-3 (Figure 1Q). The enhancer, however, CG11033
EP3093
had a minimal effect on toxicity of full-length Ataxin-3
(unpublished data). This indicated that the modiﬁers varied
in strength and selectivity depending upon whether the
Ataxin-3 protein was intact or truncated. As truncation may
be a feature of SCA3 disease [28–30], the effectiveness of
modiﬁers against different forms of Ataxin-3 has implications
for disease pathogenesis.
Ataxin-3 Modifiers Affect General Protein Misfolding
Previous studies have shown that the molecular chaperone
Hsp70 is a potent suppressor of SCA3 toxicity [31]. Therefore,
we considered that the class 1 modiﬁers may function similar
to Hsp70 to help cells handle the misfolded disease protein,
whereas those of class 2 likely have a role in ubiquitin-
dependent pathways that process misfolded proteins. How-
ever, class 3 presented a range of potential activities. To
address how the modiﬁers were functioning biologically, we
tested whether the modiﬁers could affect a general protein
misfolding phenotype: compromised chaperone activity with
a dominant-negative form of Hsp70 (Hsp70.K71E). This
situation results in an eye phenotype that resembles severe
polyQ degeneration (Figure 2A and [32]). Thus, modiﬁers that
affected both SCA3 and Hsp70.K71E toxicity would likely
include those whose mode of action was to modulate protein
misfolding.
Strikingly, we found that most of the suppressors of polyQ
toxicity also mitigated the Hsp70.K71E phenotype, as well as
or better than directed expression of Hsp70 itself (Figure 2;
Table 1). Interestingly, DnaJ-1
B345.2 and Tpr2
EB7-1A enhanced
this phenotype; we interpreted this to indicate that these
genes, which encode proteins thought to act as cochaperones
of Hsp70, may compromise residual Hsp70 in the dominant-
negative situation. The chaperone mrj
E1050, although an
Hsp40 class chaperone, acted in a manner distinct from
DnaJ-1
B345.2, as it suppressed rather than enhanced the
Hsp70.K17E phenotype. Moreover, the enhancer of
SCA3trQ78 toxicity, CG11033
EP3093, suppressed the misfold-
ing phenotype. Only one modiﬁer did not affect this
phenotype, the ubiquitin protease Ubp64E
E213-1A; interest-
ingly, normal Ataxin-3 also has ubiquitin protease activity
that mitigates its own pathogenicity, and similarly, has no
effect on Hsp70.K71E [15]. We considered that one mecha-
nism by which the modiﬁers may mitigate the Hsp70.K71E
phenotype is by upregulating Hsp70/Hsc70 chaperones;
however, none of the modiﬁers appeared to act in this way
(Figure 2K and unpublished data). These results indicated
that the majority of modiﬁers of SCA3trQ78 toxicity
appeared to function biologically by aiding in situations of
compromised chaperone activity and/or protein misfolding.
Reduced Accumulation of the Pathogenic Protein
Reduces Toxicity
The degree of neurodegeneration induced by pathogenic
polyQ protein is typically correlated with the level of
accumulation of the protein in animals in vivo. We reasoned,
therefore, that the modiﬁers may affect protein levels. We
therefore examined protein accumulation by immunohisto-
chemistry and western analysis. Although nuclear inclusions
may not be causal in disease [33], later onset, smaller nuclear
inclusions are typically reﬂective of reduced pathogenicity of
the protein in vivo. Hsp70 and Hsp40 have also been shown
to increase the solubility of pathogenic polyQ protein by
western blots, concomitant with reducing toxicity [16]. We
therefore examined protein accumulation using rh1-GAL4 or
the full-length Ataxin-3 protein—both situations that allow
sensitive analysis of protein accumulation [15,22]. In these
studies, we limited analysis to the strong and moderate
modiﬁers.
Immunohistochemical analysis revealed that select modi-
ﬁers had striking effects to reduce NIs. These included the
Figure 1. Modifiers of SCA3trQ78-Induced Neurodegeneration in Drosophila Eye and Internal Retinal Sections of 1-d Flies
(A) Control with normal eye and retinal thickness (white arrow). Genotype w; gmr-GAL4/þ.
(B) Expression of strong SCA3trQ78 causes external and internal degeneration, with pigment loss and severely reduced retinal thickness. Genotype w;
gmr-GAL4 UAS-SCA3trQ78/þ.
(C–E) Class 1 suppressors Hsp68
E407, mrj
E1050, and CG14207
EP1348 rescued external eye pigmentation and restored the internal eye towards normal.
Genotypes w; gmr-GAL4 UAS-SCA3trQ78 in trans to alleles indicated.
(F and G) Class 3 suppressors emb
E128-1A and dbr
EP9 have strong and weak rescue. Genotypes w; gmr-GAL4 UAS-SCA3trQ78 in trans to alleles indicated.
(H–J) Co-expression of CG11033
EP3093 with SCA3trQ61 severely enhances pigment loss and internal retinal degeneration; expression of CG11033
EP3093
alone has no effect. Genotypes (H) w; gmr-GAL4 UAS-SCA3trQ61/þ, (I) w; gmr-GAL4 UAS-SCA3trQ61 in trans to CG11033
EP3093, and (J) w; gmr-GAL4 in trans
to CG11033
EP3093.
(K–O) Deletions for regions that uncover select modifier genes enhance Ataxin-3 degeneration, suggesting dose sensitivity of these modifiers. (K)
Pathogenic Ataxin-3 causes neuronal degeneration. (L) Ataxin-3 in trans to Df(3L)CH20, which uncovers both DnaJ-1 and Ubp64E, is lethal and causes
severe degeneration (pupal eye shown). (M–O) Ataxin-3 in trans to deficiencies uncovering Tpr2 (Df(2L)r10), emb (Df(2L)TE29A), or dbr (Df(2L)PM44).
Genotypes (K) w; gmr-GAL4 UAS-SCA3trQ78/þ, (L) w; gmr-GAL4 UAS-SCA3trQ78 /þ; Df(3L)CH10/þ, (M) w;gmr-GAL4 UAS-SCA3trQ78/ Df(2L)r10, (N) w;gmr-
GAL4 UAS-SCA3trQ78/ Df(2L)TE29A, and (O) w;gmr-GAL4 UAS-SCA3trQ78/ Df(2L)PM44.
(P and Q) Modifiers functionally restore vision. (P) Flies with normal vision chose light when given a choice between light and dark chambers; flies
expressing SCA3tr-Q78 are blind, choosing light and dark in equal numbers (1-d flies). Co-expression of mrj
E1050 or CG14207
EP1348 with SCA3trQ78
restored vision toward normal. Genotypes: Canton-S, w; gmr-GAL4 UAS-SCA3trQ78 in trans to þ, mrj
E1050 or CG14207
EP1348.
(Q) Modifiers mitigate vision loss induced by full-length pathogenic Ataxin-3. Flies expressing SCA3-Q84 have strikingly compromised vision (7-d flies).
Coexpression of CG14207
EP1348 or mrj
E1050 suppressed visual defects and restored phototaxis. Mean 6 standard error of the mean of three experiments.
Genotypes w; gmr-GAL4 UAS-SCA3Q84 in trans to þ, mrj
E1050 or CG14207
EP1348.
Bar in (A), 100 lm for (A–J); bar in (K), 100 lm for (K–O).
doi:10.1371/journal.pgen.0030177.g001
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Modifiers of Ataxin-3 Neurodegenerationclass I chaperones Hsp68
E407, DnaJ-1
B345.2, mrj
E1050, but did not
include aB-crystalline CG14207
EP1348 or Tpr2
EB7-1A (Figure 3;
Table 1). Of the class 2 ubiquitin-pathway components,
polyubiquitin CR11700
EP1384 and the ubiquitin protease
Ubp64E
E213-1A reduced NIs, but the other strong modiﬁers
of this class did not. Of class 3 modiﬁers tested, all reduced NI
except Imp
EP1433 (Figure 3B and 3F). We then analyzed
solubility of the pathogenic protein by immunoblot. This
approach revealed that, although the modiﬁers had no effect
on protein levels at early time points prior to inclusion
formation, all suppressors increased the level of monomeric
protein over time, thus all increased the solubility properties
of the pathogenic protein (Figure 3E). The effect was speciﬁc,
as co-expression of a control protein (green ﬂuorescent
protein [GFP]) had no effect (unpublished data). Similarly, the
enhancer reduced monomer levels (unpublished data). These
ﬁndings indicate that the modiﬁers either affected patho-
genic protein accumulation or altered the solubility proper-
ties of the toxic protein, concomitant with altering protein
pathogenicity.
Select Modifiers Are Sensitive to In Vivo Inhibition of the
Proteasome
Given that many modiﬁers mitigated protein accumula-
tion, we asked whether there were interactions with genes of
protein degradation pathways. A key pathway thought to
modulate the pathogenic polyQ toxicity is the ubiquitin-
proteasomal system (UPS) [34]. We therefore tested whether
suppression by modiﬁers that lowered protein levels was
dependent upon a fully functional proteasome. Proteasome
activity can be reduced by a dominant temperature-sensitive
mutation in a proteasome protein subunit (DTS5) [35]. In a
situation where limiting proteasome activity using this
mutation had no effect on SCA3 toxicity on its own, we
found that a striking number of modiﬁers still suppressed
polyQ toxicity, thus indicating that they were not sensitive to
inhibition of the proteasome by this assay; these included dpld
alleles (Figure 4; Table 1). In contrast, a striking exception was
the class 2 ubiquitin-pathway suppressors: all of these
modiﬁers lost the ability to suppress upon proteasome
inhibition with the DTS mutation.
Pathogenic Ataxin-3 Stimulates Autophagy, with Select
Modifiers Promoting and Others Preventing Autophagy
Autophagy, or lysosome-mediated protein degradation, has
also been implicated in polyQ toxicity and cell survival in
situations of stress [36,37]. We therefore asked whether the
modiﬁer genes had an effect on this process. First, we
determined whether normal or pathogenic Ataxin-3 itself
induced lysosomal accumulation reﬂective of autophagy, by
examining the fat body tissue from larvae, a standard assay
for autophagy [38]. Normally, well-fed animals show minimal
lysosomal induction, whereas starved animals show a dramat-
ic increase, reﬂected by the uptake of dye (Figure 4F and 4G).
Whereas expression of normal Ataxin-3 (SCA3Q27) had
minimal effect, expression of pathogenic Ataxin-3-induced
autophagy (Figure 4J). To further address the role of
autophagy, we determined whether limiting the activity of
autophagy genes affected SCA3 toxicity. Key genes to which
RNA interference transgenic lines are available include Atg5.
Whereas reduction of Atg5 activity on its own had little effect,
reducing Atg5 in the presence of pathogenic SCA3 protein
appeared to enhance toxicity, with increased loss of retinal
integrity (Figure 4L–4N). This suggests that, normally,
autophagy may mitigate toxicity of the pathogenic protein.
Reduction of autophagy also enhanced aggregation of the
protein by western immunoblot and enhanced cytoplasmic
protein accumulation along photoreceptor axons (Figure
4O–4Q).
We then determined whether strong modiﬁer genes also
modulated autophagy. We examined two situations: (1) to
determine whether strong modiﬁer genes could induce
autophagy in well-fed animals when autophagy is normally
minimal; (2) to determine whether they could block autoph-
agy under starvation, when autophagy is stimulated as a
protective mechanism. We tested these as we considered that
a modiﬁer may affect Ataxin-3 pathogenicity either by
inducing autophagy-mediated lysosomal degradation of the
pathogenic protein, or alternatively, by blocking autophagy if
autophagy contributes to loss of the cells in response to
Figure 2. EP Modifiers Strongly Affect General Protein Misfolding Defects
(A) Compromised endogenous Hsp70 via expression of a dominant
negative Hsp70 transgene (UAS-Hsp70.K71E) leads to a degenerate eye.
Genotype w; gmr-GAL4 UAS-Hsp70.K71E/þ.
(B–H) The chaperone modifiers (B) Hsp68
E407 and (C) CG14207
EP1348
partially rescue Hsp70.K71E. (D) An enhancer of Ataxin-3 toxicity
(CG11033
EP3093) also suppresses general misfolding, suggesting that
Ataxin-3 toxicity and misfolding do not have identical molecular
mechanisms. (E) emb
E2-1A, (F) Sin3A
B9-E, (G) NFAT
EP1335, and (H) Imp
EP1433
also suppress the Hsp70.K71E phenotype suggesting a role of these
modifiers in protein quality control. Genotypes w; gmr-GAL4 UAS-
Hsp70.K71E in trans to (B) Hsp68
E407, (C) CG14207
EP1348, (D) CG11033
EP3093,
(E) emb
E2-1A, (F) Sin3A
B9-E, (G) NFAT
EP1335, and (H) Imp
EP1433.
(I and J) Cochaperones DnaJ-1
B345.2 and Tpr2
EB7-1A are pupal lethal upon
expression with Hsp70.K71E, causing more severe misfolding phenotype.
Genotype w; gmr-GAL4 UAS-Hsp70.K71E in trans to EP lines (I) B345.2 and
(J) EB7-1A. Bar in (A), 100 lm for (A–J).
(K) Western blot indicates that the modifiers do not induce expression of
Hsp70. Protein samples from the 1-d fly head, with indicated genotypes,
gmr-GAL4 driver. Positive control, 7-d flies expressing UAS-SCA3trQ78.
doi:10.1371/journal.pgen.0030177.g002
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Modifiers of Ataxin-3 Neurodegenerationmutant polyQ protein. These studies revealed that select
modiﬁers induced, whereas others mitigated, autophagy
(Figure 4H, 4I, and 4K). Of the class 1 chaperone modiﬁers,
the two Hsp40 genes (DnaJ-1
B345.2 and mrj
E1050) increased
autophagy, whereas Hsp70 and the class 3 modiﬁer Imp
EP1433
reduced autophagy. Although Dpld showed no effect in these
assays, limiting autophagy by reduction of Atg5, Atg7,o rAtg12
mitigated Dpld suppression, suggesting that its activity was
dependent on autophagy (Figure 4R, 4S, and unpublished
data). These and other data (Figures S8 and S9) suggested that
Dpld may act upstream of autophagy genes to activate
autophagy in select situations. We also tested available GFP
protein trap lines to examine localization of modiﬁer
proteins. Although none of these lines showed GFP immu-
nostaining, one line with a protein trap insertion in Hsc70Cb
enhanced SCA3 neuronal toxicity and increased protein
accumulation in the neurophil similar to autophagy genes
(Figure S8G–S8K). Taken together, these studies indicated
that the modiﬁers, despite broad molecular nature, mitigated
situations of protein misfolding; in some cases their activity
appeared dependent on the proteasome, whereas others may
involve autophagy-based protein clearance or autophagy-
related cell loss.
Select Modifiers Affect Other Pathogenic Human Disease
Models
The modiﬁers were selected based on ability to modulate
SCA3 degeneration; however, our studies suggested that the
modiﬁers may have broader functions in protein misfolding.
We therefore determined whether they could modulate
toxicity of tau. Abnormal accumulation of tau in neuro-
ﬁbrillary tangles or mutations in tau are associated with
Alzheimer disease and frontotemporal dementia [39]. Tau-
induced degeneration is mitigated by the caspase inhibitor
P35 and DIAPs, implicating programmed cell death pathways
in tau toxicity [40]. Expression of normal (tau.wt) or mutant
(tau.R406) tau causes toxicity reﬂected in a reduced and
degenerate eye [41]. Co-expression of the class 1 chaperone
Tpr2
EB7-1A and the Hsc70Cb line class 2 modiﬁer polyubiquitin
CR11700
EP1384, and class 3 modiﬁers dpld
JM265, Imp
EP1433, and
CG5009
B227.2 strikingly suppressed toxicity of tau (Figure 5;
Figure S8). The class 3 modiﬁer emb
E2-1A enhanced tau (Figure
5), whereas NFAT
EP1335 enhanced tau.wt, but had no effect on
mutant tau.R406W (unpublished data). We then examined the
ability of the modiﬁers to affect programmed cell death.
Several class 3 modiﬁers had an effect on hid-induced eye loss:
co-expression of emb
E2-1A and NFAT
EP1508 enhanced hid,
whereas Imp
EP1433 and dpld
JM265 alleles suppressed hid-induced
cell death (Figure 5 and unpublished data). Alleles of those
genes that modulated tau and programmed cell death
similarly (emb, dpld, NFAT, and Imp) may modulate tau toxicity
by altering cell death. In contrast, the others (Tpr2,
polyubiquitin CR11700, and Hsc70Cb) likely modulate tau
toxicity through other means. Taken together, these data
indicate that select modiﬁers that inﬂuence cell survival and
protein misfolding may be common to both SCA3 and tau-
induced degeneration.
Discussion
We present a detailed functional analysis of genetic
modiﬁers of pathogenic Ataxin-3 induced neuronal toxicity.
Figure 3. Modifiers Affect Accumulation or Solubility of Ataxin-3 Protein
(A–D) Horizontal cryosections of 1-d flies indicate two modes of activity
of suppressors on disease protein accumulations: reduction or no effect.
(A) Control flies showing NI of full-length SCA3Q84 protein. Genotype w;
gmr-GAL4 UAS-SCA3Q84 /þ.
(B) Imp
EP1433 has no effect on NI. Genotype Imp
EP1433; gmr-GAL4 UAS-
SCA3Q84/þ.
(C) Hsp68
E407 and (D) CG5009
B227.2 decrease NI. Genotypes (C) w; gmr-
GAL4 UAS-SCA3Q84/þ; E407/þ and (D) w; gmr-gal4 UAS-SCA3Q84 /B227.2.
(E) Western blot shows that all suppressors increase the solubility of the
disease protein. Normally, no monomer is seen in the line expressing
strong SCA3trQ78 (lane 1). Upon co-expression of suppressors, monomer
level of disease protein increases, indicative of increased solubility.
Genotype w; gmr-GAL4 UAS-SCA3Q84 in trans to indicated suppressors.
(F and H) Horizontal retinal sections of 7-d flies.
(F) NI in flies expressing SCA3trQ78 are strongly reduced by Dpld.
(H) Endogenous Hsp70 stress response is also strongly reduced by Dpld.
Genotypes (F–H left panel) w; UAS-SCA3trQ78/þ; rh1-GAL4 /þ and (F–H
right panel) w; UAS-SCA3trQ78/þ; rh1-GAL4 / dpld
J990-P2.
(I) Western blots of 7-d flies showing that reduced stress response, as
determined by levels of endogenous Hsp70, correlates with increased
solubility of disease protein. Dpld increases disease protein monomer
level and reduces stress-induced Hsp70. Genotype w; UAS-SCA3trQ78;
rh1-GAL4 in trans to þ, dpld
J990-P2, dpld
JM265, dpld
JM265ex, and hHsp70.
doi:10.1371/journal.pgen.0030177.g003
PLoS Genetics | www.plosgenetics.org October 2007 | Volume 3 | Issue 10 | e177 1956
Modifiers of Ataxin-3 NeurodegenerationPLoS Genetics | www.plosgenetics.org October 2007 | Volume 3 | Issue 10 | e177 1957
Modifiers of Ataxin-3 NeurodegenerationThe majority of modiﬁers fell into chaperone and ubiquitin
pathways, consistent with the proposed function of Ataxin-3
in the ubiquitin-proteasome pathway, as well as pathways
implicated in polyQ toxicity. Strikingly, however, biological
assays for the activity of modiﬁers, some of which are
predicted to function in diverse biological processes, in-
dicated that their activities also converge on protein
misfolding. Several protein quality control pathways appear
involved, including the UPS and autophagy. These ﬁndings
underscore the signiﬁcance of protein quality control path-
ways to SCA3 and potentially other age-dependent protein
conformation diseases.
A Genetic Screen for Modifiers That Mitigate PolyQ
Degeneration
Our screen was designed to identify upregulation modi-
ﬁers, targeting genes whose increased activity could modulate
neuronal toxicity and degeneration of a pathogenic Ataxin-3
protein. This screen identiﬁed activities that may become
compromised or normally insufﬁcient in the disease protein
situation. A number of modiﬁers appeared dosage sensitive,
in that reduction of the genetic region encoding the gene
enhanced degeneration. This suggests that, at least for select
modiﬁers, their normal activity is also critical for main-
tenance of neurons in disease.
Because of the severity of the degenerate eye, we may have
selected for particularly strong modiﬁers. Modiﬁers were also
initially selected for the ability to mitigate an external eye
degeneration, rather than direct neuronal toxicity. Despite
this, all of the modiﬁers mitigated internal neural degener-
ation. This indicates that the degree of external eye
degeneration is a reasonable predictor of internal neuronal
integrity. A number of modiﬁers were identiﬁed multiple
times (dpld, NFAT, emb, and dbr), although most were found
only once, indicating that the screen is not saturated.
Additional screens using different mutagens or different
types of screening approaches may reveal additional and
different classes of modiﬁers. Although the modiﬁers were
selected for mitigation of toxicity of a truncated Ataxin-3
protein, nearly all effectively mitigated toxicity of the full-
length pathogenic protein. Our previous and other studies
suggest that truncation may normally occur in disease to
remove the N-terminal ubiquitin protease domain and would
dramatically enhance degeneration [15,29,30]. Therefore,
these are efﬁcacious modiﬁers that mitigate toxicity of
various forms of the pathogenic protein.
Chaperones and Ubiquitin-Pathway Components Are
Critical Regulators of SCA3
The majority of modiﬁers were either chaperones or, by
sequence and functional tests, modulated ubiquitin-mediated
protein quality control pathways. Whereas those that have
sequence implications in this pathway might be anticipated, a
surprise was that many genes with widely divergent molecular
activities were functionally implicated in this process. These
data suggest that many genes can modulate situations of
protein misfolding, and moreover, suggest that protein
misfolding is central to polyQ pathogenesis. It is also possible
that, given the normal function of Ataxin-3 in ubiquitin-
modulated pathways, the screen selected for modiﬁers that
impinge on normal activities of Ataxin-3. Among the
modiﬁers, some decreased protein accumulation, whereas
others suppressed with no apparent change in Ataxin-3
inclusions. Of those that decreased Ataxin-3 accumulation,
some appeared dependent on functional proteasome activity,
whereas others stimulated autophagy, or both, implicating
various mechanisms that attenuate Ataxin-3 degeneration.
Among the modiﬁers was polyubiquitin, arguing that the level
of ubiquitin itself may normally be insufﬁcient to handle the
misfolded protein over prolonged periods. This is consistent
with the lack of a robust stress response to pathogenic polyQ
[42]. In a Caenorhabditis elegans of model of polyQ, Gidalevitz et
al. [43] reveal that polyQ expansions can cause temperature-
sensitive alleles of various unrelated genes (paramyosin,
Figure 4. Degradation Pathways of Ataxin-3-Induced Neurodegeneration
(A–E) External eyes of 1-d flies showing suppression of SCAtrQ78 toxicity by modifiers only (upper panel), and suppression by modifiers in limited
proteasome background (lower panel) by expression of a dominant negative form of a 20S proteasome subunit [35].
(A) Limiting proteasome activity alone does not enhance Ataxin-3 degeneration. Genotype (upper panel) w; gmr-GAL4 UAS-SCA3trQ78 /þ and (lower
panel) w; gmr-GAL4 UAS-SCA3trQ78/þ ; UAS-DTS5/þ.
(B and C) Polyubiquitin CR11700
EP1384 (B) and Ubp64E
E213-1A (C) cannot suppress when proteasome activity is limited. Genotypes (B) EP1384; gmr-GAL4
UAS-SCA3trQ78 /þ; UAS-DTS5/þ and (C) w; gmr-GAL4 UAS-SCA3trQ78/þ; UAS-DTS5/E213-1A.
(D and E) DnaJ-1
B345.2 and dpld
JM265 suppression remain largely unaffected when proteasome activity is limited. Genotypes (D) w; gmr-GAL4 UAS-
SCA3trQ78/þ; UAS-DTS5/ B345.2 and (E) w; gmr-GAL4 UAS-SCA3trQ78/JM265; UAS-DTS5/þ.
(F–I) Fat body tissues from larvae under starved or fed conditions, stained by Lysotraker Red (red) to highlight lysosomes and Hoescht (blue) for nuclei.
Starvation strongly induces lysosomes (F), whereas fed animals normally have limited lysosomes (G). Ubiquitous expression of DnaJ-1 upregulates the
induction of lysosomes in the fat bodies in starvation conditions (H), suggesting that DnaJ-1 may reduce NI in a disease situation by facilitating
autophagy. Imp suppresses starvation-induced autophagy (I) although has no effect on NI, raising the possibility that it may modulate autophagic cell
death. Genotypes (F–G) w, (H) w; da-GAL4/B345.2, and (I) EP1433;da-GAL4/þ.
(J and K) Scores of autophagy. Average values were obtained from at least 20 larvae per genotype. Error bar represents standard error of the mean of
multiple experiments.
(J) In fed conditions, pathogenic Ataxin-3 induces autophagy but normal Ataxin-3 has little effect.
(K) In starvation conditions, expression of Ataxin-3, DnaJ-1, and Mrj further induce autophagy; on the contrary, Hsp70 and Imp suppress starvation-
induced autophagy.
(L–N) Retinal sections. (L) Flies (1 d) expressing SCA3Q84 have some loss of retinal integrity, which is mildly enhanced by reduction of (M) Atg5. (N)
Reduction of atg5 activity alone has normal retinal morphology. Genotypes (L) w; gmr-GAL4 UAS-SCA3Q84/þ, (M) UAS-Atg5_IR/UAS-Atg5_IR; gmr-GAL4
UAS-SCA3Q84/þ, and (N) gmr-GAL4/þ; UAS-Atg5_IR/UAS-Atg5_IR.
(O) Western blot showing that reduction of Atg5 decreases Ataxin-3 monomer level, concomitant with enhanced toxicity.
(P and Q) Cryosections for disease protein (1-d flies, anti-myc). Reduction of autophagy increases disease protein accumulation in the lamina (Q)
compared to disease protein alone control (P). Hsc70.K71S also enhances, but it does not cause similar protein accumulations in the retina (unpublished
data). Genotype in (P) is same as (L), and (Q) is same as (M).
(R and S) Paraffin sections (1-d flies) showing suppression of Ataxin-3 degeneration by Dpld and that Dpld suppression is reduced by limiting
autophagy. Genotypes (R) w; gmr-GAL4 UAS-SCA3trQ78 /JM265 and (S) UAS-Atg7_IR; gmr-GAL4 UAS-SCA3trQ78/JM265.
doi:10.1371/journal.pgen.0030177.g004
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Modifiers of Ataxin-3 Neurodegenerationdynamin, and ras) to display the mutant effect at what would
normally be permissive conditions. This ﬁnding suggests that
long polyQ runs can cause a general disruption of the cellular
protein-folding environment to affect the temperature-
sensitive mutant proteins. Our work used a pathogenic
human disease protein Ataxin-3 and revealed that many
modiﬁers that mitigate Ataxin-3 toxicity also modulate
general protein misfolding. Taken together, these results
suggest that, in the absence of upregulation of the various
components needed, the cell may become overwhelmed,
triggering deleterious effects [32]. Our detailed analysis of
modiﬁers of Ataxin-3 have revealed a variety of biological
processes that can help manage pathogenic polyQ protein, as
well as speciﬁc genes of interest (Figure 6A).
The precise molecular pathways by which those modiﬁers
that are not clearly within protein folding pathways can
modulate misfolding to affect neurodegeneration requires
further study. We envisage, however, that they function by
their predicted molecular mechanisms, but on targets that
impinge on cellular protein homeostasis. For example,
chromatin modiﬁers may tweak the expression of a variety
of genes in such processes, whereas translational regulators
may translationally modify such genes. The ﬁnding that a
variety of cellular functions are involved would be consistent
with RNA interference screens in C. elegans that identiﬁed a
variety of genes that impinge on cellular protein homeostasis
as enhancers of the aggregation of polyQ protein [20]. These
ﬁndings, along with other studies including those we present
here, underscore the critical importance of proper protein
homeostasis to most—if not all—cellular functions, such that
a variety of genes can inﬂuence this process.
Among our modiﬁers, some that might have been expected
to act in a similar manner, appeared to have distinct
biological effects. The class 2 modiﬁers showed complete
dependence on proper proteasome activity, while other
modiﬁers, including alleles of DnaJ-1 and Imp, appeared to
be insensitive to limiting proteasome activity, but rather
affected autophagy in stress conditions. Hsp70 suppresses
multiple stress conditions including protein misfolding,
starvation-induced autophagy, and paraquat-induced oxida-
tive stress [11], suggesting it may both facilitate UPS activity,
but also block autophagy-dependent degeneration. In vivo,
these pathways interplay to maintain proper neuronal
function in the face of disease, thus further study of the
modiﬁers may allow greater molecular identiﬁcation of the
individual pathways, as well as their integration.
Although only select modiﬁers affected protein accumu-
lation as assayed by immunohistochemistry, all affected the
solubility of the disease protein by biochemical analysis. The
relationship between protein inclusions and proposed toxic
oligomers is still under investigation, but it seems reasonable
to suggest that the change in solubility may reﬂect activity of
the modiﬁers to buffer or alter toxic conformations of the
protein. Our efforts to detect toxic oligomers of Ataxin-3
using available antibodies [33,44,45] are still in progress. We
note that, despite gross similarity, SCA3 degeneration is not
identical to general misfolding: some suppressors of Ataxin-3
toxicity strikingly enhanced dominant-negative Hsp70 (upre-
gulation of DnaJ-1 and Tpr2), whereas the enhancer
CG11033
E3093 suppressed it.
The UPS and autophagy pathways function in either
degeneration or polyQ protein pathogenicity [46]. Our
Figure 5. Select Ataxin-3 Modifiers also Modulate Tau Toxicity
(A) Top: expression of pathogenic human tau.R406W causes a rough and reduced eye [41]. Genotype w; gmr-gal4/þ; UAS-tau.R406W/þ. Bottom: Ectopic
expression of apoptotic gene hid ablates the eye. Genotype w; gmr-GAL4 gmr-hid /þ. Genes shown modulated tau.wt and tau.R406W similarly.
(B–D) Tpr2
EB7-1A (B), polyubiquitin CR11700
EP1384 (C), and CG5009
B227.2 (D) suppress pathogenic tau. Tpr2
EB7-1A (B) and CR11700
EP1384 (C) have no effect on
Hid-induced programmed cell death. Genotypes (upper panel B) w; gmr-GAL4/þ; UAS-tau.R406W /EB7-1A, (C) EP1384; gmr-GAL4/þ; UAS-tau.R406W /þ, and
w; gmr-gal4/B227.2; UAS-tau.R406W /þ. (Lower panel, B) w; gmr-GAL4 gmr-hid /EB7-1A, (C) EP1384; gmr-GAL4 gmr-hid /þ, and (D) w; gmr-GAL4 gmr-hid/
B227.2.
(E–G) dpld
JM265 (E), Imp
EP1433 (F), and emb
E2-1A (G) modulate tau toxicity and programmed cell death in a similar manner, suggesting that their effect on
taumaybeduetomodulationofcelldeath.Genotypes(upperpanel,E)w;gmr-GAL4/þ;UAS-tau.R406W/JM265,(F)EP1433;gmr-GAL4/þ;UAS-tau.R406W/þ,
and (G) w; gmr-GAL4/E2-1A; UAS-tau.R406W /þ. (Lower panel, E) w; gmr-GAL4 gmr-hid /JM265, (F) EP1433; gmr-GAL4 gmr-hid /þ, and (G) w; gmr-GAL4 gmr-
hid/E2-1A.
doi:10.1371/journal.pgen.0030177.g005
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Modifiers of Ataxin-3 Neurodegenerationﬁndings indicate that these pathways at least in part function
in the removal or decrease of the toxic protein, thereby
reducing degeneration. It is also possible that activities of
these pathways may be inhibited during pathogenesis; such
inhibition of normal activity would contribute to disease
pathology [47–49]. The normal function of Ataxin-3 is in
ubiquitin-modulated pathways [23–26]; our data suggest the
possibility that Ataxin-3 may also modulate autophagy.
Normal physiological levels of autophagy are critical to
integrity of neurons, as loss of autophagy causes degeneration
associated with ubiquitinated inclusions [50,51]. Our studies
also reveal that compromise of autophagy pathways strikingly
increased cytoplasmic Ataxin-3 accumulations in the neuro-
phil without an obvious change in NIs. This may indicate that
autophagy normally modulates cytoplasmic accumulation of
the disease protein. Previous studies show that cytoplasmic
polyQ protein is very toxic and blocks axonal transport [52].
These ﬁndings suggest that perturbations in autophagy may
enhance cytoplasmic toxicity further.
In addition to regulation of the disease protein level and
misfolding, results with select modiﬁers (Hsp70 and Imp)
suggest that autophagy may also regulate loss of the cells.
Given that our previous ﬁndings failed to reveal a clear role
of caspase-dependent cell death in SCA3 [22], autophagy may
be a mechanism of cell loss in this situation. Identiﬁcation of
other components of UPS and autophagy pathway will give
further insights into how the disease protein is degraded and
mechanisms of neuronal loss.
Relationship to Other Modifier Pathways and Screens
Genetic screens have been performed for modiﬁers of
Ataxin-1 [19] and of pure polyQ domains [18], revealing
similar components of protein folding and degradation:
DnaJ-1 [18,19] and Tpr2 [18], but also RNA binding proteins
and transcription factors. Although components of ubiquitin
pathways that modulate Ataxin-1 appear distinct from
Ataxin-3, this may reﬂect different regulators required for
modifying different proteins or lack of saturation of the
screens. Similarly several RNA binding proteins identiﬁed as
modiﬁers of Ataxin-1 were suggested to reﬂect Ataxin-1
function as a putative RNA binding protein; our data suggest
that it is also possible that these modiﬁers work more
fundamentally to modulate protein solubility or levels. Our
other work, however, has revealed a role for microRNAs in
modulating neuronal survival in neurodegenerative situa-
tions [22,53], which has recently been extended to vertebrate
neuronal integrity as well [54]. A C. elegans screen revealed a
large number of modiﬁers of a pure polyQ aggregation
phenotype [20]. Several modiﬁers identiﬁed in that screen
affect RNA synthesis, processing, and protein synthesis as
modiﬁers of misfolding. It will be important to test these
modiﬁers against various speciﬁc disease proteins, as the
action of a pure polyQ repeat may be distinct from a
pathogenic repeat within a host protein.
One reason for global commonality among modiﬁers of
polyQ disease proteins may be that the proteins themselves
fall within a common interacting protein network. Recent
studies using the yeast two-hybrid approach and proteomic
databases reveal a protein interaction network of the ataxia
proteins [55]. A surprise was that many different ataxia
proteins, including Ataxin-3, fall within a few interaction
steps from one another, suggesting that their common
phenotypes may be a reﬂection of common interactions,
which, when perturbed, contribute to disease. In that study
[55], seven proteins were identiﬁed as direct interaction
partners of Ataxin-3; however none of these appeared in our
screen. Another direct binding protein–VCP [56]—was also
not identiﬁed. However, the human orthologues of the
Figure 6. Activities of Modifier Genes of Ataxin-3-Associated Neurodegeneration
(A) Modifiers of pathogenic Ataxin-3 toxicity may (1) reduce disease protein accumulation into NI in a manner sensitive to proteasome activity and/orb y
modulating autophagy, (2) promote cellular functionality in situations of misfolded protein, and/or (3) promote neuronal survival by regulating
autophagic cell loss.
(B) Select modifiers of Ataxin-3 toxicity reveal genetic links to tau toxicity and Hid-induced programmed cell death. Tpr2
EB7-1A, polyubiquitin
CR11700
EP1384, and CG5009
B227.2 suppress both Ataxin-3 and tau toxicity, implicating chaperone and ubiquitin proteasome activity as modifiers of tau
effects. Modifiers with similar effects on tau and hid-induced cell death may be modulating tau by modulating cell death; however, these modifiers
likely act in a distinct way on Ataxin-3-associated degeneration, which is not sensitive to programmed cell death genes but rather appears modulated
by the microRNA bantam [22].
doi:10.1371/journal.pgen.0030177.g006
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Modifiers of Ataxin-3 Neurodegenerationmajority of the genetic modiﬁers we deﬁned ﬁt into the
protein interaction network at various points; some are
direct interactors of other ataxia disease proteins, and others
are one or more steps removed (Table S3).
Alzheimer disease and polyQ diseases are two unrelated
human neurodegenerative diseases that cause neuronal
degeneration in distinct brain regions [1,2,57]. Therefore,
no overlap was expected between modiﬁers of these disease
proteins in ﬂies; indeed previous studies suggest minimal
overlapping genes [58]. Surprisingly, we found that select
modiﬁers of Ataxin-3 suppressed tau-degeneration, including
the cochaperone Tpr2 and polyubiquitin (Figure 6B). This
ﬁnding is consistent with cell culture studies and C. elegans
RNA interference screens that implicate chaperones as
modiﬁers of tau degeneration [59,60]. Further study of these
modiﬁers, especially those that may be in common among
different disease proteins, should provide the foundation for
new therapeutic insight.
Materials and Methods
Drosophila stocks and crosses. Fly lines were grown in standard
cornmeal molasses agar with dry yeast at 25 8C. Transgenic lines UAS-
SCA3trQ78, UAS-SCAtrQ61, UAS-SCA3Q78, and UAS-SCA3Q84 are
described [14–16]. General stock lines, deﬁciency lines, and speciﬁc
alleles of the EP modiﬁers were obtained from the Bloomington
Drosophila stock center. The emb mutant lines were from C.
Samakovlis (Wenner-Gren Institute Stockholm University, Stock-
holm, Sweden) [61]. rh1-GAL4, gmr-hid, UAS-DTS5, autophagy
inverted repeat lines (UAS-Atg5_IR and UAS-Atg7_IR), tau trans-
genic lines (UAS-htau and UAS-htau.R406W), UAS-brat, and Hsc70C
protein trap line were kindly provided by C. Desplan (New York
University, New York, New York, United States), H. Steller (Rock-
efeller University, New York, New York, US), J.M. Belote (Syracuse
University, Syracuse, New York, US), T. Neufeld (University of
Minnesota, Minneapolis, Minnesota, US), M. Feany (Harvard Medical
School, Boston, Massachusetts, US), R. Wharton (Duke University
Medical Center, Durham, North Carolina, US), M. Buszczakl (Johns
Hopkins University, Baltimore, Maryland, US), respectively. The
dominant-negative Hsp70 line is described [32]. UAS-dpld FLAG,
untagged, and gfp fusion lines were generated from cDNA clone
LD02463 by subcloning into the pUAST vector [62]. Excision lines for
reversion were made by crossing the EP insertions to lines bearing
transposase, then screening for loss of the EP element.
For the genetic screen, virgin females of the starter line EP55,
bearing an EP insertion on the X chromosome [27], was crossed to
males with transposase. Males were selected and crossed to virgin
females that expressed the disease gene (w/w; gmr-GAL4 UAS-
SCA3trQ78 Tft/CyO). F1 progeny were screened for males with either
suppressed or enhanced eye phenotypes as compared to controls; any
modiﬁers were then outcrossed and balanced. EP insertions were
conﬁrmed to be single insertions through outcrossing, as well as
plasmid rescue.
Histochemistry. Epon sections, parafﬁn sections, and cryosections
of adult heads were performed as described [14,16]. Primary
antibodies for immunostaining were anti-HA primary antibody (Y-
11, 1:50, Santa Cruz Biotechnology; and 12CA5, 1:100, Roche), anti-
Myc (9E10, 1:100, Santa Cruz Biotechnology), anti-Hsp70 (7FB,
1:1,000,) [63], and anti-Gfp (A6455, 1:50, Molecular Probes). Secon-
dary antibodies included anti-mouse or anti-rabbit conjugated to
Alexa Fluor 594 or 488 (1:200 or 1:100, Molecular Probes). Western
immunoblots were performed as described [16]. Primary antibodies
used were HA-HRP (3F10, 1:500, Roche), rat anti-Hsp70 (7FB,
1:2,000), and mouse anti-tubulin (E7, 1:2,000, Developmental Studies
Hybridoma Bank), with the secondary goat anti-rat IgG (1:2,000,
Roche) and goat anti-mouse IgG (1:2,000, Chemicon International).
Molecular biology. To deﬁne the sites of EP insertion, plasmid
rescue was performed [27]. To conﬁrm single hits in the genome,
multiples of clones from each EP line were sequenced with an EP 39 P-
end speciﬁc primer (59-CAA TCA TAT CGC TGT CTC ACT CA-39).
The ﬂanking DNA sequence was used to query ﬂybase BLAST to
deﬁne the nearby gene and exact site of insertion. Upregulation of
the genes by the EP element was conﬁrmed by northern analysis,
comparing the EP line alone, to wild-type ﬂy controls with the EP line
in the presence of a GAL4 driver, using gene-speciﬁc probes
generated by reverse-transcription PCR using an EP-speciﬁc primer
and gene-speciﬁc primers to the target genes. That the EP insertions
were single insertions was independently veriﬁed genetically by
molecular and phenotypic analysis of lines.
The effect of the modiﬁers on transgene expression levels was
examined by real-time PCR (see Text S1 and Figure S2) and by
reverse-transcription PCR. For the latter, total RNA was extracted
with the RNAeasy kit (74104, QIAGEN) following manufacturer’s
instructions. cDNA synthesis was done using SuperScript First Strand
Synthesis for reverse-transcription PCR (12371–019, Invitrogen). PCR
was performed using primers: for the SCA3 transcript, 59-CTAT-
CAGGACAGAGTTCACAT-39 (forward) and 59-CAGATAAAGTGT-
GAAGGTAGC-39 (reverse); for the GAL4 transcript, 59-
GTCTTCTATCGAACAAGCATGCGA-39 (forward) and 59-
TGACCTTTGTTACTACTCTCTTCC-39 (reverse) and for rp49 con-
trol, 59-CCAGTCGGATCGATATGCTAA-39 (forward) and 59-AC-
CGTTGGGGTTGGTGAG-39 (reverse).
Behavioral assays. Phototaxis was performed as described [15]. The
percentage of ﬂies in the light and dark chambers represent an
average of three independent groups of ﬂies. At least 100 ﬂies were
tested for each genotype, 20 ﬂies were used in each experiment.
Autophagy assays. Third instar larval fat body tissues were stained
with Lyso Tracker Red DND-99 (L-7528, Molecular Probes) and
Hoechst (H3570, Molecular Probes) as described [38]. For each
genotype, well-fed and starved larvae were used as negative and
positive controls for the assay conditions. A score of 4 was given to
control larvae grown under starvation condition; autophagy for other
genotypes was scored relative to this. Controls (driver line alone and/
or modiﬁer alone, in starvation and well-fed conditions) were
performed for each modiﬁer genes in parallel to the experimental
situation. The ﬁnal autophagy score represents the average of 20
larvae from each genotype.
Supporting Information
Figure S1. Modiﬁers of SCA3trQ78-Associated Neurodegeneration
External eye and internal retinal sections of 1-d ﬂies.
(A) Control external and internal eye. Normal retinal thickness is
indicated with yellow arrow. Genotype w; gmr-GAL4/þ.
(B) Expression of strong SCA3trQ78 in the eye causes external and
internal degeneration with severe pigment loss and markedly reduced
retinal thickness. Genotype w; gmr-GAL4 UAS-SCA3trQ78/þ.
(C–T) Suppressors of SCA3tr-Q78 associated neurodegeneration in
trans to w; gmr-gal4 UAS-SCA3trQ78. EP lines are (C) E407, (D) B345.2,
(E) E1050,( F )EP1348, (G) EB7-1A, (H) EP1384,( I )E213-1A,(J )B3-Sa,
(K) E659, (M) E2-1A, (N) B9-E, (O) EP1335, (P) EP456,( Q )JM265, (R)
B8-S, (S) EP1433 and (T) B227.2. (L) EP3093 enhances SCA3trQ78-
associated neurodegeneration and lethality.
Found at doi:10.1371/journal.pgen.0030177.sg001 (1.9 MB JPG).
Figure S2. Control Experiments for SCA3 Modiﬁers
(A) (Top) Western analysis for SCA3trQ78 protein level (detected
with anti-HA) in 1-d ﬂy heads. Experiments were performed using the
late onset gene expression driver rh1-GAL4. At 1 d, the pathogenic
protein is soluble by immunocytochemistry and western analysis. The
Ataxin-3 protein level was similar in the various situations, indicating
that the modiﬁers do not affect expression from the GAL4-UAS
system. Genotypes: w; UAS-SCA3trQ78; rh1-GAL4 in trans to þ or the
various EP modiﬁer lines as indicated.
(A) (Bottom) Real-time PCR for level of transgenes shown are
Tpr2EB7-1A, Faf
E659, Sin3A
B9-E, dbr
EP456, dpld
JM265, orb2
B8-S, Imp
EP1433;
CG5009
B227.2 was conﬁrmed by reverse transcription PCR (unpub-
lished data). Genotypes: w; UAS-SCA3trQ78; rh1-GAL4 in trans to þor
EP modiﬁer lines indicated.
(B–F) Examples of modiﬁers that failed to affect tau toxicity. All
modiﬁers were tested for ability to modulate the deleterious effects
of a number of additional genes, including tau, hid, and others
(below). Although select modiﬁers affected tau toxicity (either to
enhance or suppress, see Figure 5), others had no effect. The
inability to modulate such additional gene activities was additional
evidence that the modiﬁers did not affect the GAL4-UAS system.
Tau-induced degenerate eye is not modulated upon co-expression
of EP alleles of (C) Hsp68, (D) Ubp64E, (E) CG11103, or (F) Sin3A.
Genotypes: (B) w; gmr-GAL4/þ; UAS-tau.R406W/þ , (C) w; gmr-GAL4/þ;
UAS-tau.R406W/ E407, (D) w; gmr-GAL4/þ; UAS-tau.R406W/ E213-1A,
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Modifiers of Ataxin-3 Neurodegeneration(E) w; gmr-GAL4/þ; UAS-tau.R406W/EP3093, and (F) w; gmr-GAL4/þ;
UAS-tau.R406W/ B9-E.
(G–K) Detailed analysis of controls for alleles of the dpld gene.
(G)WesternanalysisforSCA3trQ78proteinexpressionin1-dﬂyheads.
TheEPallele ofdpld(dpld
JM265),generatedtransgeniclinesofdpld(UAS-
dpld, dpld
J990), and the precise excision line of the dpld
JM265 allele (dpld
JM265-ex) showed similar levels of disease protein at early time points
compared to the control (þ). This indicated that upregulation of dpld
did not affect expression from the GAL4-UAS system; rather further
studies showed that Dpld affected long-term accumulation of the
protein (see Figure 3F and 3G). Genotypes: lane 1, w; UAS-
SCA3trQ78/þ; rh1-GAL/þ; lane 2, w; UAS-SCA3trQ78/dpld
JM265; rh1-
GAL4/þ; lane 3, w; UAS-SCA3trQ78/þ; rh1-GAL4/UAS-dpld
J990; lane 4,w ;
UAS-SCA3trQ78/dpld
JM265-ex; rh1-GAL4/þ.
(H–K) Effect of dpld expression on various deleterious GAL4/UAS-
induced eye phenotypes.
(H and I) dpld expression had no effect on eyeless-induced disruption
of the eye. Genotypes: (H) w; ey-GAL4 UAS-eyeless/ dpld
JM265 and (I) w/þ;
ey-GAL4 UAS-eyeless/þ.
(J and K) dpld expression did not affect the rough eye phenotype
induced by expression of MAP2. Genotypes: ( J) w; gmr-GAL4 UAS-
MAP2/ dpld JM265 and (K) w/þ; gmr-GAL4 UAS-MAP2/þ.
Found at doi:10.1371/journal.pgen.0030177.sg002 (1.0 MB JPG).
Figure S3. Conserved Domains of Modiﬁer Genes
The modiﬁers fall into three major classes based on conserved
sequence domains: genes involved in chaperone pathways, in
ubiquitin pathways, and miscellaneous functions. The conserved
domains for the ﬁrst category include Hsp70, DnaJ, DNAJ-C, Hsp20,
and tetratricopeptide repeat (TPR). The second category has
ubiquitin, ubiquitin carboxy hydrolase (UCH), ubiquitin associated
(UBA), ubiquitin regulatory (UBX), and F-box domains. The
conserved domains for the third category include Importin-beta N
terminus (IBNN), paired amphipathic helix repeat (PAH), rel
homology domain (RHD), transcription factor/cell surface receptor
immunoglobulin-like fold (TIG), RNA recognition motif (RRM), KH,
and acyl-CoA oxidase (ACOX) domain.
Found at doi:10.1371/journal.pgen.0030177.sg003 (665 KB JPG).
Figure S4. Ataxin-3 Modiﬁer Genes Mitigate Toxicity of PolyQ
Protein in the Nervous System
(A) Animals expressing SCA3trQ78 in the nervous system do not
develop to adults, with lethality of larvae and pupae that fail to form
completely (pupa shown).
(B) With co-expression of EP1050, now the animals develop to the
pharate pupal stage, with eyes, wings, and legs fully formed, though
the animals fail to emerge from the pupal case. Genotypes: (A) elav-
GAL4; UAS-SCA3trQ78(S)/þ and (B) elav-GAL4; UAS-SCA3trQ78(S)/
EP1050.
(C) Table of lethality with or without added select modiﬁer genes. *,
Lethality assessed with neuronal expression by the elav-GAL4 driver,
which is expressed in all neurons through development and in the
adult.
Found at doi:10.1371/journal.pgen.0030177.sg004 (901 KB JPG).
Figure S5. Genomic Organization of dpld
(A) Genomic organization of dpld with insertion sites of EP alleles
indicated. The A form of the dpld transcript is shown (three splice
variants are predicted), black represents exons, and blue indicates the
59 UTR and 39 UTR. EP insertions are in the same orientation as gene
expression. dpld is on 2R, cytological position 43C5. The centromere
is to the right. Restriction enzyme sites are: X, XbaI; H, HindIII; R,
EcoRI; B, BamHI; S, SacII; P, PstI.
(B) Schematic representation of Dpld protein and select homologs
(Dm Brat, Ce Lin-41, and Homo sapiens Lin-41). Blue is the B-box zinc
ﬁnger, yellow is the coiled-coil, red is NHL repeats, and pink is a ring
ﬁnger domain. The percent identity of the NHL domain to that of
Dpld is noted.
(C) NHL domain based evolutionary tree showing relatedness of Dpld
to that of other RBCC-NHL family members in nematode, ﬂy, and
human. Dpld is most homologous to Lin-41; the other studied ﬂy
NHL protein Brat is distantly related.
(D) Sequence alignment of the B1 and B2 boxes, and the NHL domain
of Dpld to those of Brat, human Lin-41, and C. elegans Lin-41. Amino
acid identities in black; similarities and identities in three of the four
sequences are in gray. The cysteine and histidine residues that deﬁne
the B-box subclass of Zn ﬁnger are marked with an asterisk (*). The
positions of NHL repeats are noted.
Found at doi:10.1371/journal.pgen.0030177.sg005 (806 KB JPG).
Figure S6. Dpld Suppresses Ataxin-3-Associated Neurodegeneration
External eye and internal retinal sections of 1-d ﬂies.
(A) Control ﬂy bearing only the driver line. Genotype w; gmr-GAL4/þ.
(B) Ataxin-3 induces severe retinal degeneration. Genotype w; gmr-
GAL4 UAS-SCA3trQ78/þ.
(C) Co-expression of dpld
JM265 with SCA3trQ78 results in normal
pigmentation and improved retinal structure. Genotype w; gmr-
GAL4 UAS-SCA3trQ78/dpld
JM265.
(D) Expression of dpld from a UAS-dpld transgene improves retinal
structure, indicating that suppression of polyQ toxicity is due to
increasedDpldactivity.Genotypew;gmr-GAL4UAS-SCA3trQ78/þ;UAS-
dpld
J990-P2/þ.
(E–G) Tangential retinal sections of ﬂy expressing SCA3trQ78 alone
or with Dpld. Flies expressing SCA3trQ78 have a normal retina (E) at
1 d, which undergoes severe progressive degeneration by (F) 21 d.
Genotype w; UAS-SCA3trQ78/þ; rh1-GAL4/þ.
(G) Flies with SCA3trQ78 and UAS-dpld
J990-P2 are normal. Genotype
UAS-SCA3trQ78/þ; rh1-GAL4 /UAS-dpld.
(H) Rhabdomere counts in individual ommatidia by optical neutral-
ized corneal pseudopupil (see reference contained in Text S1). Flies
expressing SCA3trQ78 show degeneration in the number of rhab-
domeres per ommatidial unit at 21 d. Flies expressing SCA3trQ78 and
dpld
J990-P2 retain rhabdomere numbers over 21 d; dpld
JM265 has partial
rescue compared to controls.
Found at doi:10.1371/journal.pgen.0030177.sg006 (1.5 MB JPG).
Figure S7. Select Modiﬁers More Effectively Mitigate Toxicity of Full
Length Ataxin-3
(A)Expressionoffull-lengthSCA3Q84causesamildeyedegeneration.
Genotype w; gmr-GAL4 UAS-SCA3Q84 /þ.
(B–C) The modiﬁers (B) CG14207
EP1348 and (C) polyubiquitin
CR11700
EP1384 suppress full-length disease toxicity stronger than
they do the truncated disease protein. Genotypes w; gmr-GAL4 UAS-
SCA3Q84 in trans to EP1348 and EP1384.
Found at doi:10.1371/journal.pgen.0030177.sg007 (482 KB JPG).
Figure S8. Additional Details of Dpld and Hsc70C
(A–C) Horizontal eye section of a ﬂy eye expressing dpld-eYFP shows
(B) nonhomogenous distribution and localization to membranous
structures. (A) Hoechst staining. (C) Overlay shows that Dpld does not
localize to nucleus but is concentrated around it. Genotype w; UAS-
dpld-eYFP in trans to gmr-GAL4.
(D–F) Horizontal retinal section showing Dpld localization in the
presence of SCA3trQ78. (D) eYFP staining for Dpld and (E) HA
staining for SCA3trQ78. (F) Overlay shows that Dpld is not recruited
to the SCA3trQ78 aggregates. Genotype w; gmr-GAL4 UAS-SCA3trQ78
in trans to UAS-dpld-eYFP.
(G and H) GFP insertion allele of Hsc70Cb enhances Ataxin-3
neurotoxicity. Hsc70CbGFP fusion protein was conﬁrmed by Western
immunoblot (unpublished data). The line is homozygous lethal
indicating a potential loss of function of allele of Hsc70Cb. Genotypes
w; gmr-GAL4 UAS-SCA3trQ78/þ (H) and w; gmr-GAL4 UAS-
SCA3trQ78/þ; Hsc70Cb
CB02656/þ.
(I–K) Hsc70Cb protein trap line strikingly increases Ataxin-3
inclusions in the lamina and medulla, indicating enhanced cytoplas-
mic disease protein. (I) Hoescht staining for nuclei. Genotypes gmr-
GAL4 UAS-SCA3Q84/þ (I and J), w; gmr-GAL4 UAS-SCA3Q84/þ;
Hsc70Cb
CB02656/þ.
(L–O) Hsc70Cb suppresses (L and M) normal and (N and O) mutant
R406W tau-induced degeneration. Genotypes (L) w; gmr-GAL4/þ; UAS-
tau/þ, (N) w; gmr-GAL4/þ; UAS-tau/ Hsc70Cb
CB02656, (M) w; gmr-GAL4/þ;
UAS-tau.R406W/þ,a n d( N )w; gmr-GAL4/þ; UAS-tau.R406W/
Hsc70Cb
CB02656.
Found at doi:10.1371/journal.pgen.0030177.sg008 (2.1 MB JPG).
Figure S9. Dpld Modulates Body Size
(A–F) dpld and brat share a function in growth regulation (see
reference contained in Text S1), but the activities of dpld to suppress
polyQ toxicity and cell death are special to dpld. The effect of dpld on
eye and body size were mitigated by reducing autophagy gene activity
(not shown).
(A right, and C) Dpld expression during development reduces body
size (A, ﬂy on the right) and (C) eye size, similar to brat over-
expression. Genotype in (A) w; act5C-GAL4 in trans to þ or UAS-dpld
and (C) w; ey-GAL4/UAS-dpld.
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Modifiers of Ataxin-3 Neurodegeneration(A left, B) Normal ﬂy body and eye size. Genotype (A) w; act5C-GAL4/þ
and (B) w; ey-GAL4/þ.
(D, E) Directed expression of brat does not mitigate degeneration
induced by SCA3trQ78 either (D) externally or (E) internally.
Genotype w; gmr-GAL4 UAS-SCA3trQ78 in trans to UAS-brat.
(F) Brat does not mitigate hid-induced programmed cell death.
Genotype w; gmr-hid gmr-GAL4 in trans to UAS-brat.
Found at doi:10.1371/journal.pgen.0030177.sg009 (769 KB JPG).
Table S1. Summary of Genetic Modiﬁers of Ataxin-3
The location and orientation of the EP insertions are indicated,
including the method used to conﬁrm that the insertions caused
overexpression of the targeted gene. Note that insertions into novel
genes were reverted to conﬁrm that the EP insertion was causal in
modiﬁcation.
Found at doi:10.1371/journal.pgen.0030177.st001 (98 KB DOC).
Table S2. Loss-of-Function Deﬁciency Regions and Alleles of
Modiﬁers of Ataxin-3 Neurodegeneration That Were Tested
Alleles and deﬁciency lines of Ataxin-3 modiﬁers were tested for
modulation of polyQ toxicity. See also Figure 1K–1O.
Found at doi:10.1371/journal.pgen.0030177.st002 (89 KB DOC).
Table S3. Protein Interactions of Ataxin-3 Genetic Modiﬁers
List of human orthologues of the ﬂy modiﬁers found. The degree of
interaction from Ataxin-3 is from Table 5 of Lim et al. (see reference
contained in Text S1). Degree of interaction is based on the distance
each orthologue is from the seven primary interactors deﬁned for
Ataxin-3 (ARHGAP19, EWSR1, LIN10, RAD23A, RAD23B, TEX11,
and PRKCABP) (see reference contained in Text S1) and VCP/TER94
(see reference contained in Text S1).
Found at doi:10.1371/journal.pgen.0030177.st003 (122 KB DOC).
Text S1. Supplemental Methods
Found at doi:10.1371/journal.pgen.0030177.sd001 (62 KB DOC).
Accession Numbers
The accession numbers of the proteins used in the analysis in Figure
S5 from the National Center for Biotechnology Information (NCBI)
(http://www.ncbi.nlm.nih.gov) are Dm Dappled (NM_165533),
DmCG15105 (NM_137546), Dm Brat (NM_057597), Dm Mei-P26
(NM_143765), Ce Lin-41 (NM_060086), Hs Lin-41 (XM_067369),
Hs TRIM2 (NM_015271), Hs TRIM3 (NM_006458), and Hs TRIM32
(NM_012210).
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